Opinion: The Veterinary Breach: How Medetomidine is Blindsiding Canada's Emergency Rooms

### The New Adulterant

Canada's toxic drug supply is evolving, and the latest shift is leaving emergency physicians and overdose prevention workers in a state of crisis. As CBC News first reported, a powerful synthetic veterinary sedative known as medetomidine is being added to street fentanyl. While fentanyl is already a primary driver of the national opioid epidemic, its effects are short-lived—lasting only half as long as heroin. To extend this high, dealers are turning to medetomidine.

Medetomidine has not been approved for human use, and CBC News reports that its effects on people have not been well studied. The Canadian Centre on Substance Use and Addiction (CCSA) notes that the synthetic first appeared in Quebec, B.C., and Ontario in 2023, with detections in the latter two provinces increasing substantially since then. The reach of the sedative has expanded further, appearing in the Maritime region, with Saskatchewan and Yukon experiencing sharp increases this year.

### A Failure of Harm Reduction

The drug fundamentally changes the nature of an overdose, rendering standard rescue protocols insufficient. Substance Use Philly notes that when reversing an overdose involving medetomidine, responders must focus on the patient's breathing rather than their responsiveness. This is because medetomidine is a sedative, not an opioid; consequently, it does not respond to naloxone (generically known as Narcan).

Dr. Monty Ghosh, a Calgary-based addictions physician and researcher, explains to CBC News that while opioids impair breathing, the addition of medetomidine causes patients to become significantly more drowsy, while suffering from low heart rates and low blood pressure. This is "very dangerous" because it reduces blood flow to vital organs and slows breathing. Similarly, nurses at overdose prevention sites in Montreal and B.C. expressed concern via a CCSA presentation over users becoming unresponsive and dizzy for hours, requiring constant monitoring of oxygen levels, heart rate, and pulse.

### The 'Novel Withdrawal' Crisis

A "novel withdrawal syndrome" was first flagged this fall by researchers in Philadelphia, where the sedative is common. This affects individuals with opioid use disorder in areas where medetomidine is prevalent. According to CBC News, symptoms include agitated delirium, hypertension, severely elevated heartbeat, vomiting, and reports of organ damage. Dr. Ghosh notes that these blood pressure spikes can lead to strokes or heart attacks, skewing the management strategies physicians must use.

### A System Under Siege

Dr. Sahil Gupta, a physician in Toronto, tells CBC News that patients suffering from medetomidine withdrawal require high-resource care, often needing intensive care medications or full hospitalization because consciousness and breathing must be monitored longer than with opioid withdrawal. This leads to increased overcrowding and longer wait times in emergency departments. In extreme cases, patients must be placed on ventilators to prevent the brain from starving of oxygen.

This escalation comes as Canada's Chief Public Health Officer Dr. Joss Reimer noted a 23% drop in opioid deaths in 2025. While Dr. Reimer expressed "cautious optimism," he warned on June 15 that further reductions require coordinated action as emergency services face "polysubstance overdoses" that demand complex interventions. As Dr. Gupta points out, unless the broader continuum of socioeconomic factors and homelessness are addressed, the cycle of toxicity will continue to overwhelm the system.